FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

175 letters match. Newest first.

  1. Foshan Yiying Hygiene Products Co., Ltd.

    Foshan Yiying, a Chinese OTC drug maker, lacked finished-product testing, stability data and process validation; FDA has blocked its imports.

    High risk
  2. Creative Essences, Inc.

    FDA warns Creative Essences over OTC drug manufacturing failures and an unapproved antiseptic.

    High risk
  3. Columbia Cosmetics Manufacturing Inc.

    Columbia Cosmetics Manufacturing Inc. made OTC sunscreen drugs without adequate current good manufacturing practice, including failed out-of-specification investigations and untested high-risk ingredients.

    High risk
  4. Gussyup LLC dba Private Label Grooming

    FDA found Gussyup LLC, a Henderson, Nevada OTC drug maker, lacking quality oversight and ingredient identity testing; company stopped drug production.

    High risk
  5. Medical Chemical Corporation

    FDA warned Medical Chemical Corp over manufacturing violations, unapproved Tincture Green Soap, and improper drug listing.

    High risk
  6. Nature’s Fusions LLC

    FDA cited Nature's Fusions for over-the-counter hand sanitizer manufacturing with inadequate stability, component and finished-product testing, and water controls.

    High risk
  7. Libby Laboratories, Inc.

    FDA warned Libby Laboratories of Berkeley, California, that its drug manufacturing violated CGMP, including releasing a hospital antiseptic without microbial testing.

    High risk
  8. Lystn LLC dba Answers Pet Food

    FDA warned Answers Pet Food that its raw pet food contained Salmonella and Listeria and was made under insanitary conditions.

    High risk
  9. Dynamic Blending Specialists, Inc.

    FDA cited Dynamic Blending Specialists for manufacturing failures in OTC drugs and an unapproved, misbranded oral antiseptic.

    High risk
  10. Healwell Homeo Private Limited

    FDA warns Healwell Homeo over pest-infested drug storage and manufacturing violations.

    High risk
  11. Amish Origins Management, LLC

    FDA warned Amish Origins over manufacturing quality failures and unapproved or misbranded OTC pain relief and lip balm products.

    High risk
  12. Product Society LLC

    FDA says Product Society LLC, an OTC drugmaker in North Hollywood, California, skipped identity testing for toxic DEG/EG and process validation.

    High risk
  13. Wuxi Medical Instrument Factory Co., Ltd.

    FDA warns Wuxi Medical Instrument Factory over insanitary conditions and manufacturing failures for sterile drugs.

    High risk
  14. NWL Netherlands Services B.V.

    FDA cites NWL Netherlands drug plant for inadequate microbial investigations, missing component identity testing, and weak lab data controls.

    High risk
  15. Mentha & Allied Products Private Ltd.

    FDA warns Mentha & Allied Products of CGMP failures that leave its APIs adulterated.

    High risk
  16. BioAsia Worldwide Sdn Bhd

    FDA warned BioAsia Worldwide over current good manufacturing practice violations for OTC drugs.

    High risk
  17. Dyno Manufacturing, Inc.

    Dyno Manufacturing’s OTC hand sanitizer and antibacterial soap drugs lacked raw-material identity testing and other required manufacturing controls.

    High risk
  18. BEO Pharma Inc. dba BEO Pharmaceuticals Inc.

    FDA cited BEO Pharma for manufacturing quality violations, including missing identity testing of high-risk drug ingredients and releasing a batch before microbial testing.

    High risk
  19. Yangzhou Sion Commodity Co., Ltd.

    FDA warned Yangzhou Sion Commodity over drug manufacturing failures, including untested high-risk ingredients and unreliable lab records.

    High risk
  20. Rite-Kem Incorporated

    FDA warned Rite-Kem over inadequate current good manufacturing practice testing of over-the-counter drugs, including hand sanitizers and antimicrobial products.

    High risk
  21. Vegewax Candleworx Ltd.

    FDA warns Vegewax Candleworx over CGMP violations in OTC drug manufacturing, including inadequate component testing and OOS investigations.

    High risk
  22. AmWiner & Raphe Holdings, LLC dba rapheGenerics Corp

    FDA cited rapheGenerics for manufacturing-quality failures and unapproved minoxidil hair regrowth drugs.

    High risk
  23. Chengdu Innovation Pharmaceutical Co., Ltd.

    FDA warned Chengdu Innovation Pharmaceutical over CGMP (manufacturing quality rules) failures in API (drug ingredient) manufacturing, including no identity testing of incoming materials.

    High risk
  24. Shantou Kangjie Daily Chemical Industry Co., Ltd

    FDA warns Shantou Kangjie over CGMP failures for OTC drugs, including untested ethanol and no quality unit.

    High risk
  25. Imperial Palace Commodity -Dongguan- Co., Ltd.

    FDA warns Chinese maker of OTC alcohol wipes that weak component testing and process validation make its drugs adulterated.

    High risk
  26. Guangzhou Sinocon Food Co., Ltd

    FDA warns Guangzhou Sinocon Food over food-safety violations in ready-to-eat Oat Beta Glucan powder, including pathogen hazards and inaccurate test certificates.

    High risk
  27. Bhargava Phytolab Private Limited

    FDA warns Bhargava Phytolab over drug and API current good manufacturing practice (CGMP) violations, including inadequate testing and sterility controls.

    High risk
  28. Sombra Cosmetics, Inc.

    FDA warned Sombra Cosmetics of OTC drug CGMP violations, including inadequate water controls and component testing.

    High risk
  29. Dr. Brite, LLC

    FDA cited Dr. Brite for manufacturing quality failures and selling unapproved, misbranded oral care and hand sanitizer drugs.

    High risk
  30. LCC Ltd.

    FDA warned LCC Ltd. over manufacturing-quality failures, contamination testing gaps, discarded lab data, and unapproved mouthwash drugs.

    High risk
  31. Zhejiang Uniquality Nursing Products Technology Co., Ltd. dba ZheJiang YouQuan Care Products Technology Co., Ltd.

    FDA warns Zhejiang Uniquality over inadequate OTC drug component testing and quality oversight; import alert issued.

    High risk
  32. Eurosirel S.P.A

    FDA warns Eurosirel over CGMP failures in topical drugs and pain patches, including missing glycerin identity testing.

    High risk
  33. Originitalia SRL

    FDA warns Originitalia SRL over manufacturing quality failures in OTC drugs, including untested active ingredient and missing release testing.

    High risk
  34. Multaler et Cie SAS

    FDA cites Multaler et Cie for manufacturing failures and unapproved sunscreen after April 2024 inspection.

    High risk
  35. Diora Kimya Sanayi ve Ticaret Limited Sirketi

    FDA cited Diora Kimya for drug manufacturing quality failures and for an unlisted antibacterial soap.

    High risk
  36. Little Moon Essentials, LLC

    FDA warns Little Moon Essentials over CGMP failures and unapproved topical analgesic drugs made in Dania Beach, Florida.

    High risk
  37. Far East Summit LLC

    FDA says Far East Summit sold herbal supplements as unapproved drugs and made them under serious manufacturing violations.

    High risk
  38. Diamond Chemical Co., Inc.

    Diamond Chemical Co. in East Rutherford, NJ, made OTC hand sanitizers without required ingredient and finished-product testing or process validation.

    High risk
  39. Clean Solutions LLC

    FDA warned Clean Solutions LLC that its OTC hand soaps and sanitizer were adulterated because it released drugs without component or finished-product testing.

    High risk
  40. Aerosol and Liquid Packaging, Inc.

    FDA warns Aerosol and Liquid Packaging on CGMP failures and unapproved antiseptic spray claims.

    High risk
  41. Greco Gas, Inc.

    Greco Gas, Inc. released medical gases without identity or purity testing and without quality oversight.

    High risk
  42. Orean Personal Care Ltd.

    FDA warned Orean Personal Care Ltd. that repeat manufacturing failures make its OTC drugs adulterated.

    High risk
  43. Kaylaan LLC

    FDA warns Kaylaan LLC that its fluoride toothpaste tablets were made without release testing, raw material identity testing, and adequate CGMP controls.

    High risk
  44. Intercos Europe S.p.A

    FDA warned Intercos Europe S.p.A over current good manufacturing practice violations in OTC sunscreen drugs, including missing glycerin DEG/EG testing and poor investigations.

    High risk
  45. Genuine Virgin Aloe Corp dba Triderma

    FDA warned Triderma, an Anaheim OTC skin cream maker, of CGMP violations after a January 2024 inspection.

    High risk
  46. Max Chemical Inc.

    FDA warned Max Chemical Inc. in San Juan, Puerto Rico, that its OTC drug manufacturing violated CGMP, making its drugs adulterated.

    High risk
  47. ARG Laboratories, Inc.

    FDA found ARG Laboratories released failing over-the-counter drug lots, lacked manufacturing controls, and marketed two unapproved pain creams.

    High risk
  48. reBom Co., Ltd.

    reBom failed current good manufacturing practice for OTC drugs, including inadequate stability and component testing.

    High risk
  49. Sani-Care Salon Products, Inc.

    FDA warns Sani-Care Salon Products over CGMP failures in hand sanitizer manufacturing, including inadequate quality oversight and testing.

    High risk
  50. Fancystage Unipessoal, LDA

    FDA warned Portugal OTC drug maker Fancystage Unipessoal of repeated CGMP failures, untested ingredients, unvalidated processes and misbranded fluoride mouthwash.

    High risk